Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Integra LifeSciences excels in Q2 amidst compliance challenges and growth opportunities

Integra LifeSciences delivered a strong Q2 performance, focusing on operational improvements and compliance enhancements to drive long-term growth and sustainability.
While facing challenges such as revenue impacts from compliance investments and margin pressures, the company remains resilient with a strategic focus on market positioning and efficiency.
With updated guidance, successful acquisition integration, and a CEO search underway, Integra is poised to navigate challenges and capitalize on opportunities for future success.

Integra LifeSciences appoints new CEO amidst revenue challenges in Q3

Integra LifeSciences faced revenue challenges in Q3 2024 due to supply issues and compliance plan implementation. The company announced Mojdeh Poul as the new CEO to drive operational excellence and growth. Despite challenges, revenue diversification and financial stability were maintained, with a focus on future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Integra investments or would like to inquire about potentially pursuing claims to recover your loss under th.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Integra LifeSciences Holdings Corporation (IART) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) investors concerning the Company's possible violations of federal securities laws. On May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMed, PriMatrix, Revize, and TissueMend products manufactured at its Boston facility as far back as March 1, 2018. The Company attributed the recall t.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Integra LifeSciences Holdings Corporation (IART) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMed, PriMatrix, Revize, and TissueMend products manufactured at its Bosto.

The Law Offices of Frank R. Cruz Announces Investigation of Integra LifeSciences Holdings Corporation (IART) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Integra LifeSciences Holdings Corporation (NASDAQ: IART) resulting from allegations that Integra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Integra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contin.

IART INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Integra LifeSciences Holdings Corporation Investors to Inquire About Securities Class Action Investigation – IART

Integra announced a global recall of products made at its Boston facility. The company is also temporarily halting production at the facility.

Why Integra LifeSciences Stock Is Crashing Today

Integra Lifesciences Holdings Corp (NASDAQ:IART) shares fell hard after it disclosed that after consultations with the US Food and Drug Administration (FDA) it has initiated a “voluntary global recall” of all products manufactured in its Boston facility distributed between March 1, 2018, and May 22, 2023. The Princeton, New Jersey-based medical device manufacturing company said that it expects it will incur an impairment charge related to the write-off of inventories, net of approximately $22 million.

Integra LifeSciences tumbles after product recall

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Integra (IART) Builds Advanced R&D Facility in New Jersey

New facility is dedicated to Dr. Richard E. Caruso, late company founder New facility is dedicated to Dr. Richard E. Caruso, late company founder

Integra LifeSciences Opens New Center of Innovation and Learning

In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.

Integra's (IART) Q1 Earnings Match Estimates, Margins Contract

Integra LifeSciences Holdings Corporation (IART) Q1 2023 Earnings Call Transcript.

Integra LifeSciences Holdings Corporation (IART) Q1 2023 Earnings Call Transcript

Integra LifeSciences (IART) came out with quarterly earnings of $0.74 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.74 per share a year ago.

Integra LifeSciences (IART) Q1 Earnings Meet Estimates

PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2023.

Integra LifeSciences Reports First Quarter 2023 Financial Results

PRINCETON, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2023 financial results on Wednesday, April 26, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host First Quarter 2023 Financial Results Conference Call on April 26, 2023

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Jeffrey Mosebrook - SVP, Chief Accounting Officer Mathieu Aussermeier - VP, Corporate FP&A, Investor Relations & Treasurer Conference Call Participants Vik Chopra - Wells Fargo Steve Lichtman - Oppenheimer & Co. Matthew Taylor - Jefferies Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Jayson Bedford - Raymond James David Turkaly - JMP Securities Matthew O'Brien - Piper Sandler Operator Thank you for standing by and welcome to Integra LifeSciences Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Integra LifeSciences Holdings Corporation (IART) Q4 2022 Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates

PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023.

Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

PRINCETON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release fourth quarter 2022 financial results on Wednesday, February 22, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023

Exact Sciences

Medtronic

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Integra (IART) Could Beat Earnings Estimates Again

Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials

PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.

Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope

PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).

News for Integra LifeSciences Holdings Stock (IART)